MeiraGTx Holdings (MGTX) Other Non-Current Liabilities (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Other Non-Current Liabilities came in at $1.4 million in Q4 2025, down 50.41% YoY from $2.8 million in Q4 2024, and up 2.49% on a QoQ basis from $1.4 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Other Non-Current Liabilities data on file, last reported at $1.4 million in Q4 2025.
- Quarterly Other Non-Current Liabilities fell 50.41% year-over-year to $1.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.4 million (down 50.41% YoY) and the FY2025 annual result came in at $1.4 million, down 50.41% from the prior year.
- Other Non-Current Liabilities advanced to $1.4 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q3 2024 to a low of $1.3 million in Q1 2025.
- A 5-year average of $2.1 million and a median of $2.1 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities rose 24.19% — and 2025, when it plunged 52.6%.
- Tracing MGTX's Other Non-Current Liabilities over 5 years: stood at $2.1 million in 2021, then grew by 4.71% to $2.2 million in 2022, then advanced by 10.19% to $2.4 million in 2023, then increased by 17.49% to $2.8 million in 2024, then plunged by 50.41% to $1.4 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.5 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.45 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.34 Mn |
| Dec 31, 2024 | 2.82 Mn |
| Sep 30, 2024 | 2.88 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Mar 31, 2024 | 2.44 Mn |
| Dec 31, 2023 | 2.40 Mn |
| Sep 30, 2023 | 2.32 Mn |
| Jun 30, 2023 | 2.30 Mn |
| Mar 31, 2023 | 2.24 Mn |
| Dec 31, 2022 | 2.18 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Jun 30, 2022 | 2.10 Mn |
| Mar 31, 2022 | 2.11 Mn |
| Dec 31, 2021 | 2.08 Mn |
| Sep 30, 2021 | 1.92 Mn |
| Jun 30, 2021 | 1.90 Mn |